Gilteritinib for treating relapsed or refractory acute myeloid leukaemia – guidance (TA642)

Gilteritinib monotherapy is recommended as an option for treating relapsed or refractory FLT3‑mutation +ve AML in adults. It should not be given as maintenance therapy after a haematopoietic stem cell transplant.

National Institute for Health and Care Excellence